Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
Melissa K. Thomas, Amir Nikooienejad, Ross Bray, et al.
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 106, Iss. 2, pp. 388-396
Open Access | Times Cited: 207

Showing 1-25 of 207 citing articles:

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Stefano Del Prato, Steven E. Kahn, Imre Pávó, et al.
The Lancet (2021) Vol. 398, Iss. 10313, pp. 1811-1824
Closed Access | Times Cited: 434
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Bernhard Ludvik, Francesco Giorgino, Esteban Jódar, et al.
The Lancet (2021) Vol. 398, Iss. 10300, pp. 583-598
Closed Access | Times Cited: 421
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
Naveed Sattar, Darren K. McGuire, Imre Pávó, et al.
Nature Medicine (2022) Vol. 28, Iss. 3, pp. 591-598
Open Access | Times Cited: 241
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S3, pp. 5-29
Closed Access | Times Cited: 219
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Michael A. Nauck, Jakob Wefers, Juris J. Meier
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 8, pp. 525-544
Closed Access | Times Cited: 207
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
Rohit Loomba, Mark L. Hartman, Eric Lawitz, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 4, pp. 299-310
Closed Access | Times Cited: 195
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Thomas Karagiannis, Ioannis Avgerinos, Aris Liakos, et al.
Diabetologia (2022) Vol. 65, Iss. 8, pp. 1251-1261
Open Access | Times Cited: 184
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
Tim Heise, Andrea Mari, J. Hans DeVries, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 6, pp. 418-429
Closed Access | Times Cited: 167
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Ricardo J. Samms, Michael E. Christe, Kyla Collins, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 12
Open Access | Times Cited: 150
Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Vivek P. Chavda, Jinal Ajabiya, Divya Teli, et al.
Molecules (2022) Vol. 27, Iss. 13, pp. 4315-4315
Open Access | Times Cited: 123
Tirzepatide: First Approval
Yahiya Y. Syed
Drugs (2022) Vol. 82, Iss. 11, pp. 1213-1220
Closed Access | Times Cited: 87
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial
Takashi Kadowaki, Rina Chin, Akichika Ozeki, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 9, pp. 634-644
Open Access | Times Cited: 85
GLP-1 and GIP receptor signaling in beta cells – A review of receptor interactions and co-stimulation
Ashok Mayendraraj, Mette M. Rosenkilde, Lærke S. Gasbjerg
Peptides (2022) Vol. 151, pp. 170749-170749
Open Access | Times Cited: 83
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
Christophe De Block, Clifford J. Bailey, Carol Wysham, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 3-17
Open Access | Times Cited: 71
Tirzepatide for Obesity Treatment and Diabetes Prevention
Ania M. Jastreboff, Carel W. le Roux, Adam Stefański, et al.
New England Journal of Medicine (2024)
Closed Access | Times Cited: 48
Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents
Jingqian Su, Yingsheng Luo, Shan Hu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13381-13381
Open Access | Times Cited: 46
2022 FDA TIDES (Peptides and Oligonucleotides) Harvest
Othman Al Musaimi, Danah Al Shaer, Fernando Alberício, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 336-336
Open Access | Times Cited: 43
Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database
Mansour Tobaiqy, Hajer Elkout
International Journal of Clinical Pharmacy (2024) Vol. 46, Iss. 2, pp. 488-495
Open Access | Times Cited: 32
Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor
Ajit Regmi, Eitaro Aihara, Michael E. Christe, et al.
Cell Metabolism (2024) Vol. 36, Iss. 7, pp. 1534-1549.e7
Open Access | Times Cited: 27
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Qiyuan Keith Liu
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 18
Tirzepatide prevents neurodegeneration through multiple molecular pathways
Rosaria Anna Fontanella, Puja Ghosh, Ada Pesapane, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 17
Tirzepatide: A Review in Type 2 Diabetes
Nicole L. France, Yahiya Y. Syed
Drugs (2024) Vol. 84, Iss. 2, pp. 227-238
Closed Access | Times Cited: 17
The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
Jonathan M. Wilson, Amir Nikooienejad, Deborah Robins, et al.
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 12, pp. 2451-2459
Open Access | Times Cited: 122
Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
Valentina Pirro, Kenneth D. Roth, Yanzhu Lin, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 2, pp. 363-378
Open Access | Times Cited: 83
Page 1 - Next Page

Scroll to top